L’hyperglycémie provoquée par voie orale (HGPO) revisitée 1re partie : Tolérance au glucose, diabète gestationnel et hypoglycémie réactive

Scheen, André; Luyckx, Françoise

doi:10.1016/S1957-2557(10)70124-3

Article (Scientific journals)

L’hyperglycémie provoquée par voie orale (HGPO) revisitée 1re partie : Tolérance au glucose, diabète gestationnel et hypoglycémie réactive

Scheen, André; Luyckx, Françoise

2010 • In Médecine des Maladies Métaboliques, 4 (5), p. 569-574

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/79389

DOI
10.1016/S1957-2557(10)70124-3

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

L’hyperglycémie provoquée par voie orale (HGPO).pdf

Publisher postprint (1.76 MB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Diabète gestationnel; maladies cardiovasculaires; , hyperglycémie provoquée par voie orale; , diminution de la tolérance au glucose; diabète de type 2

Abstract :

[fr] L’hyperglycémie provoquée par voie orale (HGPO) a été très utilisée pour diagnostiquer un diabète sucré, un diabète gestationnel, une diminution de la tolérance au glucose, voire une hypoglycémie réactionnelle. Cependant, depuis une dizaine d’années, certains ont proposé de limiter l’utilisation de ce test dynamique au profit de la mesure soit de la glycémie à jeun, soit de l’hémoglobine glyquée. Néanmoins, pratiquement toutes les grandes études récentes font référence à l’HGPO comme test de référence. Dans ce premier article, nous focaliserons notre attention sur l’intérêt potentiel de l’HGPO comme épreuve diagnostique et pronostique capable d’évaluer la régulation glycémique. Dans un second article, nous décrirons comment utiliser l’HGPO pour dériver des indices évaluant quantitativement l’insulinosécrétion et/ou l’insulinosensibilité.
[en] Oral glucose tolerance test (OGTT) has been widely used for the diagnosis of diabetes mellitus, gestational diabetes, impaired glucose tolerance or reactive hypoglycemia. Since almost 10 years, however, it has been proposed to limit the use of this dynamic test, favoring instead the measurement of either fasting plasma glucose or glycated hemoglobin. Nevertheless, almost all recent important studies used OGTT as reference test. In this first article, we will consider the potential interest of OGTT as diagnostic or prognostic test able to evaluate glucose regulation. In a second article, we will describe how to use OGTT to derive indices that quantitatively evaluate insulin secretion and/or insulin sensitivity.

Disciplines :

Endocrinology, metabolism & nutrition

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale

Luyckx, Françoise ; Université de Liège - ULiège > Chimie médicale

Language :

French

Title :

L’hyperglycémie provoquée par voie orale (HGPO) revisitée 1re partie : Tolérance au glucose, diabète gestationnel et hypoglycémie réactive

Alternative titles :

[en] The Oral Glucose Tolerance Test (OGTT) revisited First part: Glucose tolerance, gestational diabetes and reactive hypoglycemia

Publication date :

2010

Journal title :

Médecine des Maladies Métaboliques

ISSN :

1957-2557

eISSN :

2214-8477

Publisher :

Masson, Issy-les-Moulineaux, France

Volume :

Issue :

Pages :

569-574

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

http://www.em-consulte.com/produit/mmm

Available on ORBi :

since 14 December 2010

Statistics

Number of views

1997 (26 by ULiège)

Number of downloads

45529 (275 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

American Diabetes Association. Clinical Practice Recommendations 2010. Position statement. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl 1):S62-9.
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report on the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
Luyckx FH, Scheen AJ. L'hyperglycémie provoquée par voie orale. 1. De la controverse à un plaidoyer pour sa place en biologie clinique. Immuno-Anal Biol Spéc 2003;18:126-32.
Hanefeld M, Koehler C, Fuecker K, et al; Impaired Glucose Tolerance for Atherosclerosis and Diabetes study. Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: The risk factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes study. Diabetes Care 2003;26:868-74.
Unwin N, Shaw J, Zimmet P, et al. Impaired glucose tolerance and impaired fasting glycaemia: The current status on definition and intervention. Diabet Med 2002;19:708-23.
Faerch K, Borch-Johnsen K, Holst JJ, et al. Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: Does it matter for prevention and treatment of type 2 diabetes? Diabetologia 2009;52:1714-23.
Scheen AJ. Antidiabetic agents in subjects with mild dysglycaemia: Prevention or early treatment of type 2 diabetes? Diabetes Metab 2007;33:3-12.
Scheen AJ. Pharmacological prevention of type 2 diabetes. In: Ekoe J-M, Rewers M, Williams R, Zimmet P, editors. The Epidemiology of Diabetes Mellitus. London, UK: Wiley-Blackwell; 2008. Chapter 29:449-74.
Lefebvre PJ, Luyckx AS. The breakfast tolerance test: A return to physiology. Diabete Metab 1976;2:15-9.
Luyckx FH, Scheen AJ. Comment j'explore... les anomalies du métabolisme glucidique, de l'insulinosécrétion et de la sensibilité à l'insuline avec une hyperglycémie provoquée par voie orale. Rev Med Liège 2001;55:881-5.
Luyckx FH, Scheen AJ. L'hyperglycémie provoquée par voie orale. Étude de la sécrétion, de la clairance et de l'action de l'insuline, et du rétrocontrôle par les hormones de la contre-régulation. Immuno-Anal Biol Spéc 2003;18:185-90.
Scheen AJ, Luyckx FH. L'hyperglycémie orale revisitée. 2e partie: Indices d'insulinosécrétion, d'insulinosensibilité et de disposition orale. Médecine des maladies Métaboliques 2010; en préparation.
Gerstein HC, Santaguida P, Raina P, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: A systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract 2007;78:305-12.
Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: A systematic review of the evidence. J Am Coll Cardiol 2010;55:1310-7.
Sorkin JD, Muller DC, Fleg JL, et al. The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: Data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care 2005;28:2626-32.
Abdul-Ghani MA, Stern M P, Lyssenko V, et al. Minimal contribution of fasting hyperglycemia to the incidence of type 2 diabetes in subjects with normal 2-h plasma glucose. Diabetes Care 2010;33:557-61.
Abdul-Ghani MA, Lyssenko V, Tuomi T, et al. The shape of plasma glucose concentration curve during OGTT predicts future risk of type 2 diabetes. Diabetes Metab Res Rev 2010;26:280-6.
Abdul-Ghani MA, Williams K, DeFronzo R, et al. Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose. Diabetes Care 2006;29:1613-8.
Abdul-Ghani MA, Lyssenko V, Tuomi T, et al. Fas ting versus postload plasma glucose concentration and the risk for future type 2 diabetes: Results from the Botnia Study. Diabetes Care 2009;32:281-6.
Mostafa SA, Khunti K, Srinivasan BT, et al. The potential impact and optimal cut-points of using glycated haemoglobin, HbA1c, to detect people with impaired glucose regulation in a UK multi-ethnic cohort. Diabetes Res Clin Pract 2010;90:100-8.
Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010;362:800-11.
Cederberg H, Saukkonen T, Laakso M, et al. Postchallenge glucose, HbA1c, and fasting glucose as predictors of type 2 diabetes and cardiovascular disease: A 10-year prospective cohort study. Diabetes Care 2010;33:2077-83.
De Caterina R, Madonna R. Impaired fasting plasma glucose and long-term cardiovascular risk: Still a foggy relationship. Eur Heart J 2010;31:1159-62.
Lefèbvre PJ, Scheen AJ. The postprandial state and risk of cardiovascular disease. Diabet Med 1998;15(Suppl 4):S63-8.
Ceriello A, Davidson J, Hanefeld M, et al; International Prandial Glucose Regulation Study Group. Postprandial hyperglycaemia and cardiovascular complications of diabetes: An update. Nutr Metab Cardiovasc Dis 2006;16:453-6.
The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999;354:617-21.
DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: Comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397-405.
Ning F, Tuomilehto J, Pyörälä K, et al; DECODE Study Group. Cardiovascular disease mortality in Europeans in relation to fasting and 2h plasma glucose levels within a normoglycemic range. Diabetes Care 2010; Apr. 27 [Epub ahead of print].
Barr EL, Boyko EJ, Zimmet PZ, et al. Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: The Australian Diabetes, Obesity, and Lifestyle (AusDiab) study. Diabetologia 2009;52:415-24.
International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, Persson B, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010;33:676-82.
HAPO Study Cooperative Research Group, Metzger BE, Lowe L P, Dyer AR, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008;358:1991-2002.
Coustan DR, Lowe L P, Metzger BE, et al; International Association of Diabetes and Pregnancy Study Groups. The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: Paving the way for new diagnostic criteria for gestational diabetes mellitus. Am J Obstet Gynecol 2010;202:654.e1-6.
Kakad R, Anwar A, Dyer P, et al. Fasting plasma glucose is not sufficient to detect ongoing glucose intolerance after pregnancy complicated by gestational diabetes. Exp Clin Endocrinol Diabetes 2010;118:234-6.
Retnakaran R, Shah BR. Abnormal screening glucose challenge test in pregnancy and future risk of diabetes in young women. Diabet Med 2009;26:474-7.
Vambergue A, Dognin C, Boulogne A, et al. Increasing incidence of abnormal glucose tolerance in women with prior abnormal glucose tolerance during pregnancy: DIAGEST 2 study. Diabet Med 2008;25:58-64.
Lefèbvre PJ, Andreani D, Marks V, et al. Statement on "post-prandial" or "reactive" hypoglycemia. Diabetologia 1988;31:68-9.
Brun J F, Fedou C, Mercier J. Postprandial reactive hypoglycemia. Diabetes Metab 2000;26:337-51.
Scheen AJ, Lefèbvre PJ. Hypoglycémie réactive. In: Grimaldi A, Cosserat J, éditeurs. Les pathologies dites fonctionnelles. Paris:Elsevier; 2003. p. 109-13.
Tack J, Arts J, Caenepeel P, et al. Pathophysiology, diagnosis and management of postoperative dumping syndrome. Nat Rev Gastroenterol Hepatol 2009;6:583-90.
Goldfine AB, Mun EC, Devine E, et al. Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. J Clin Endocrinol Metab 2007;92:4678-85.
Kim SH, Liu TC, Abbasi F, et al. Plasma glucose and insulin regulation is abnormal following gastric bypass surgery with or without neuroglycopenia. Obes Surg 2009;19:1550-6.
Lefèbvre PJ, Scheen AJ. The use of acarbose in the prevention and treatment of hypoglycaemia. Eur J Clin Invest 1994;24(Suppl. 3):40-4.
Sørensen M, Johansen OE. Idiopathic reactive hypoglycaemia - Prevalence and effect of fibre on glucose excursions. Scand J Clin Lab Invest 2010;70:385-91.